DKM 2-93
Based on 5 publication(s) in Google Scholar
DKM 2-93 is a relatively selective inhibitor of UBA5 with an IC50 of 430 μM.
Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.
- Reinheit: 98.85%
- CAS. Nr.: 65836-72-8
- Formel: C11H14ClNO3
- Molecular Weight:243.69
-
Speicherung:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 2 years , -20°C, 1 year
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biologische Aktivität
-
Chemical Information
-
Lösungsmittel & Löslichkeit
- Protokoll
- Reinheit & Dokumentation
- Verweise
-
Help & FAQs
-
Oxygen Sensing Compound Library
HY-L045
-
Ubiquitination Compound Library
HY-L050
-
Anti-Pancreatic Cancer Compound Library
HY-L077
-
Anti-Liver Cancer Compound Library
HY-L101
-
Metabolic Enzyme Compound Library
HY-L146
-
Cysteine Targeted Covalent Library
HY-L153
-
Cysteine Targeted Covalent Fragment Library
HY-L154
-
Highly Selective Inhibitors Library
HY-L158
-
Mitophagy Compound Library
HY-L180
-
Bioactive Compound Library Max
HY-L181
-
MCE Bioactive Compound Library
HY-L001V
-
Bioactive Compound Library
HY-L001
-
Amino Acid Metabolism Compound Library
HY-L189
-
Cell Proliferation Compound Library
HY-L201
-
High-Throughput Bioactive Compound Library
HY-L205
-
Posttranslational Modification Library
HY-L226
-
Metabolism/Protease Compound Library
HY-L012
-
Anti-Cancer Compound Library
HY-L025
Publications Citing Use of MedChemExpress (MCE) DKM 2-93
More
Customer Validation & Images
-
WB
-
Cell Imaging/Staining
-
Histological Imaging/Staining
-
WB
-
Cell Proliferation/Viability Assay
Biologische Aktivität
IC50: 430 μM (UBA5), 90 μM (PaCa2 cells), 30 μM (Panc1 cells)[1]
Ubiquitin-like modifier activating enzyme 5 (UBA5) is a novel pancreatic cancer therapeutic target. DKM 2-93 impairs pancreatic cancer cell survival through covalently modifying the catalytic cysteine of UBA5, thereby inhibiting its activity as a protein that activates the ubiquitin-like protein UFM1 to UFMylate proteins. DKM 2-93 inhibits PaCa2 and Panc1 cells survival with IC50s of 90 and 30 μM, respectively[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Chemical Information
-
CAS. Nr. 65836-72-8
-
Appearance Solid
-
Molecular Weight 243.69
-
Formel C11H14ClNO3
-
Color White to light yellow
-
SMILES
O=C(NCC1=CC=C(OC)C(OC)=C1)CCl
-
Versand
Room temperature in continental US; may vary elsewhere.
-
Speicherung
Powder -20°C 3 years 4°C 2 years In solvent -80°C 2 years -20°C 1 year
Publications (5)
-
Journal Impact Factor
-
Most Recent
-
Nat Commun
The UFL1-AKT positive feedback loop promotes breast cancer progression by enhancing lipid synthesis. [Abstract]2026 Jan 20;17(1):614. PMID: 41559041
DKM 2-93 purchased from MedChemExpress. Usage Cited in: Nat Commun. 2026 Jan 20;17(1):614. [Abstract]
In MDA-MB-231 and MDA-MB-468 cells treated with 20 μM DKM 2-93 (UFMylation inhibitor), 6 μM MK-2206 (AKT inhibitor), or a combination of both for 24 hours, the levels of AKT1 UFMylation and phosphorylation were detected by IP and IB.
DKM 2-93 purchased from MedChemExpress. Usage Cited in: Nat Commun. 2026 Jan 20;17(1):614. [Abstract]
Representative images of the breast cancer cell lines shown, stained with 20 μM DKM 2-93 using BODIPY staining.
DKM 2-93 purchased from MedChemExpress. Usage Cited in: Nat Commun. 2026 Jan 20;17(1):614. [Abstract]
In tumor-bearing mice treated with a combination of DKM 2-93 (40 mg/kg) and MK-2206, we observed significantly reduced tumor volume and lipid content compared to mice treated with DKM 2-93 or MK-2206 alone.
-
Cell Death Dis
BRD4 inhibition suppresses histone H4 UFMylation to increase ferroptosis sensitivity through TXNIP. [Abstract]2025 Nov 17;16(1):843. PMID: 41249136
DKM 2-93 purchased from MedChemExpress. Usage Cited in: Cell Death Dis. 2025 Nov 17;16(1):843. [Abstract]
Changes in the levels of cyclin A2, MAD2, and total protein UFMylation after cells were treated with 30 μM DKM 2-93.
DKM 2-93 purchased from MedChemExpress. Usage Cited in: Cell Death Dis. 2025 Nov 17;16(1):843. [Abstract]
Cell survival rate was assessed by treating cells alone with increasing concentrations of RSL3 or in combination with 30 μM DKM 2-93.
-
Cancer Lett
CDK5RAP3 is a novel super-enhancer-driven gene activated by master TFs and regulates ER-Phagy in neuroblastoma. [Abstract]2024 Jun 1:591:216882. PMID: 38636893 -
Cell Rep
Genome-Wide CRISPR-Cas9 Screens Expose Genetic Vulnerabilities and Mechanisms of Temozolomide Sensitivity in Glioblastoma Stem Cells. [Abstract]2019 Apr 16;27(3):971-986.e9. PMID: 30995489 -
Lösungsmittel & Löslichkeit
DMSO : 125 mg/mL (512.95 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
Konzentration (Stammlösung) × Volumen (Stammlösung) = Konzentration (Ziellösung) × Volumen (Ziellösung)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.08 mg/mL (8.54 mM); Clear solution
This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.08 mg/mL (8.54 mM); Clear solution
This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
For the following dissolution methods, please prepare the working solution directly:
It is recommended to prepare fresh solutions and use them promptly within a short period of time.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 50% PEG300 50% Saline
Solubility: 25 mg/mL (102.59 mM); Clear solution; Need ultrasonic
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL.
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Protokoll
PaCa2 and Panc1 cells are treated with 0-1000 μM DKM 2-93 for 48 hours. Cell viability is assessed by Hoescht stain[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Mice: Mice are subcutaneously injected with PaCa2 cells to initiate the tumor xenograft study and treatments of mice are initiated with vehicle or DKM 2-93 (50 mg/kg ip, once per day) three days after injection of cancer cells[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Reinheit & Dokumentation
-
Data Sheet (273 KB)
-
SDS (644 KB)
- English - EN (644 KB)
- Français - FR (644 KB)
- Deutsch - DE (644 KB)
- Norwegian - NO (644 KB)
- Español - ES (644 KB)
- Swedish - SV (644 KB)
- Italian - IT (644 KB)
- Korean - KR (644 KB)
- Portuguese - PT (644 KB)
-
Handling Instructions (2659 KB)
Verweise
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 4.1036 mL | 20.5179 mL | 41.0357 mL | 102.5894 mL |
| 5 mM | 0.8207 mL | 4.1036 mL | 8.2071 mL | 20.5179 mL | |
| 10 mM | 0.4104 mL | 2.0518 mL | 4.1036 mL | 10.2589 mL | |
| 15 mM | 0.2736 mL | 1.3679 mL | 2.7357 mL | 6.8393 mL | |
| 20 mM | 0.2052 mL | 1.0259 mL | 2.0518 mL | 5.1295 mL | |
| 25 mM | 0.1641 mL | 0.8207 mL | 1.6414 mL | 4.1036 mL | |
| 30 mM | 0.1368 mL | 0.6839 mL | 1.3679 mL | 3.4196 mL | |
| 40 mM | 0.1026 mL | 0.5129 mL | 1.0259 mL | 2.5647 mL | |
| 50 mM | 0.0821 mL | 0.4104 mL | 0.8207 mL | 2.0518 mL | |
| 60 mM | 0.0684 mL | 0.3420 mL | 0.6839 mL | 1.7098 mL | |
| 80 mM | 0.0513 mL | 0.2565 mL | 0.5129 mL | 1.2824 mL | |
| 100 mM | 0.0410 mL | 0.2052 mL | 0.4104 mL | 1.0259 mL |
DKM 2-93 Related Classifications
HY-101836 Related Classifications
Powered by Bioz